Clinical Trial Update: PolyArginine Treated vEiN grafTs (PATENT) [Phase 1, Phase 2]

View source ↗

Summary

The Phase 1/2 trial evaluating PolyArginine-treated vein grafts for Saphenous Vein Graft Disease has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Saphenous Vein Graft Disease

Drugs mentioned

• PolyArginine (poly-arginine)

Snippet

Sponsor: Lumen Therapeutics | Conditions: Saphenous Vein Graft Disease | Phase 1, Phase 2 | Status: TERMINATED